Table 2.
Patient exposure and malignancies in RECORD
| Variable | Background sulfonylurea | Background metformin | ||
|---|---|---|---|---|
| Metformin | Rosiglitazone | Sulfonylurea | Rosiglitazone | |
| n | 1,122 | 1,103 | 1,105 | 1,117 |
| Study exposure (person-years) | 6,126 | 6,110 | 6,146 | 6,228 |
| Malignancies, n (%) | 69 (6.1) | 56 (5.1) | 74 (6.7) | 57 (5.1) |
| Rate (per 100 person-years)a | 1.15 | 0.94 | 1.23 | 0.93 |
| HR (95% CI) | 1.22 (0.86–1.74) | 1.33 (0.94–1.88) | ||
Data are based on number (n) of patients; malignancies are those reported as serious adverse events excluding non-melanoma skin cancers
aAdjusted for study exposure